Приказ основних података о документу

dc.creatorRmandić, Milena
dc.creatorVasilić, Đorđe
dc.creatorRašević, Marija
dc.creatorZečević, Mira
dc.creatorOtašević, Biljana
dc.creatorProtić, Ana
dc.creatorMalenović, Anđelija
dc.date.accessioned2023-10-03T13:30:15Z
dc.date.available2023-10-03T13:30:15Z
dc.date.issued2023
dc.identifier.issn1424-8247
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/5055
dc.description.abstractIn this study, an AQbD-compliant chaotropic chromatography method for ziprasidone and the determination of its five impurities was developed. The influence of critical method parameters (initial and final methanol fraction in the mobile phase, gradient duration) on the set of selected critical method attributes (t_imp. V, t_imp. V − t_imp. I, S and <WUSP>) was studied by Box–Behnken design. The errors resulting from the calculation of the model coefficients were propagated to the selected responses by Monte Carlo simulations, and their predictive distribution was obtained. The design space was computed (π ≥ 80%), and a working point was selected: initial methanol fraction 38.5%, final methanol fraction 77.5%, and gradient duration 16.25 min. Furthermore, the quantitative robustness of the developed method was tested using the Plackett–Burman design. P_imp II and P_imp V were found to be significantly affected, the first by mobile phase flow rate and the second by gradient duration. Finally, the method was validated, and its reliability for routine quality control in capsules was confirmed.
dc.publisherMDPI
dc.relationinfo:eu-repo/grantAgreement/MESTD/inst-2020/200161/RS//
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourcePharmaceuticals
dc.subjectanalytical quality by design
dc.subjectchaotropic chromatography
dc.subjectimpurities
dc.subjectrobustness testing of method quantitative performances
dc.subjectziprasidone
dc.titleDevelopment of Analytical Quality by Design Compliant Chaotropic Chromatography Method for Ziprasidone and Its Five Impurities Determination
dc.typearticle
dc.rights.licenseBY
dc.citation.volume16
dc.citation.issue9
dc.citation.rankM21~
dc.identifier.doi10.3390/ph16091296
dc.identifier.pmid37765104
dc.identifier.scopus2-s2.0-85172212846
dc.identifier.fulltexthttp://farfar.pharmacy.bg.ac.rs/bitstream/id/13946/Development_of_Analytical_pub_2023.pdf
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу